文献速递免疫规划传染病防控与疫情报告

一项II/III期、多中心、观察者盲法、随机、非劣效性与安全性研究:比较EuTCV与Typbar-TCV®在6月龄至45岁健康参与者中的免疫原性和安全性

A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV® in healthy 6 Months-45 years aged participants.
PubMed 文献 · Vaccine · 2023-02-09

在菲律宾6月龄至45岁健康参与者中开展的II/III期多中心观察者盲法随机研究显示,单剂EuTCV在99.4%的受种者中产生血清阳转,血清阳转率非劣效于Typbar-TCV®;EuTCV各批次第4周几何均值比的90%CI均落在0.5至2.0等效界值内;两组征集性和非征集性治疗中出现的不良事件比例相当。

要点

  • 单剂EuTCV在99.4%的受种者中产生血清阳转,血清阳转率非劣效于Typbar-TCV®。
  • EuTCV各批次第4周几何均值比的90%CI均位于0.5至2.0等效界值内,结论为批次间一致性。
  • EuTCV组与Typbar-TCV®组的征集性和非征集性治疗中出现的不良事件比例相当。

核心结论

  • 在健康参与者中,EuTCV与Typbar-TCV®相比具有相当的安全性和可观的免疫原性,达到了这项关键研究的目标。

研究设计与样本

  • II/III期、多中心、观察者盲法、随机、非劣效性与安全性研究(NCT04830371),在菲律宾6月龄至45岁健康参与者中开展。
  • 参与者接种试验疫苗(A组、B组和C组)或对照疫苗Typbar-TCV®(D组)。
  • 在接种前(第1次访视)和接种后(第4次访视,第28天)采集血清样本以评估EuTCV和Typbar-TCV®的免疫原性。
  • 研究期间通过定期门诊访视监测参与者并报告任何与疫苗相关的不良事件。

主要发现

  • 单剂EuTCV在99.4%的受种者中产生血清阳转,血清阳转率非劣效于Typbar-TCV®。
  • 基于第4周EuTCV A组、B组和C组几何均值比的90%CI均落在0.5至2.0等效界值内,得出批次间一致性结论。
  • EuTCV组与Typbar-TCV®组的征集性和非征集性治疗中出现的不良事件比例均相当。

关键数值与推荐

  • 单剂EuTCV血清阳转率为99.4%,血清阳转率非劣效于Typbar-TCV®。
  • EuTCV A组、B组和C组第4周几何均值比的90%CI均落在0.5至2.0等效界值内。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The typhoid conjugate vaccine (TCV) ensures a long-lasting protective immune response, requires fewer doses and is fit for children under 2 years of age. From Phase I study, EuTCV displayed considerable immunogenicity and reliable safety, thus endorsing further examination in Phase II/III trials. Therefore, a clinical Phase II/III study (NCT04830371) was conducted to evaluate its efficacy in healthy Filipino participants aged 6 months to 45 years through administration of the test vaccine (Arm A, B, and C) or comparator vaccine Typbar-TCV® (Arm D). Sera samples were collected pre-vaccination (Visit 1) and post-vaccination (Visit 4, Day 28) to assess the immunogenicity of EuTCV and Typbar-TCV®. During the study, participants were regularly monitored through scheduled visits to the clinic to report any adverse events associated with the vaccine. For vaccine safety, the proportion of solicited and unsolicited Treatment-Emergent Adverse Events was all comparable between EuTCV and Typbar-TCV® groups. A single dose of EuTCV produced seroconversion in 99.4% of treated participants, with seroconversion rates non-inferior to that of Typbar-TCV®. Batch-to-batch consistency was concluded based on the 90% Confidence Interval of the geometric mean ratio (EuTCV Arm A, B, and C) at Week 4, lying within the equivalence margin of 0.5 to 2.0 for all batches. Results from this Phase II/III clinical trial of EuTCV in healthy volunteers show comparable safety and considerable immunogenicity, compared to Typbar-TCV®, meeting the objectives of this pivotal study. ClinicalTrials.gov registration number: NCT04830371.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ok Baik Y, Lee Y, Lee C, et al. A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV® in healthy 6 Months-45 years aged participants. Vaccine. 2023. PMID: 36774331. doi:10.1016/j.vaccine.2022.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。